Brief: Travere Therapeutics Q3 EPS USD -0.7 Vs. IBES Estimate USD -0.66
31/10/2024 11:00
Oct 31 (Reuters) - Travere Therapeutics Q3 operating expenses USD 119.047 million. * Q3 operating income USD -56.149 million vs. IBES estimate USD -53.3 million * Q3 net income USD -54.811 million * Q3 product sales USD 61.001 million vs. IBES estimate USD 59.6 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule